Skip to content

Study · Randomized controlled trial · n = 10 · 1996

3 results

Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism.

Winer KK, Yanovski JA, Cutler GB Jr

JAMA1 Aug 1996Cited by 122 (Europe PMC)

PMID8773636 (opens in a new tab)DOI10.1001/jama.1996.03540080053029 (opens in a new tab)PepBankPUB-08773636
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with hypoparathyroidism, once-daily PTH maintained serum calcium within the normal range.

    In plain wordsIn hypoparathyroidism patients, once-daily PTH maintained normal blood calcium during comparison with calcitriol and calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSerum calcium maintenance
    Study

    n = 10

    Comparator
    Calcitriol and calcium
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    Once daily · subcutaneous · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Once-daily treatment with PTH 1-34 maintained serum calcium in the normal range with decreased urine calcium excretion (P<.05 at 2 weeks and P<.Ol at 10 weeks) compared with calcitriol treatment.
    5 context sentences
    Summary · context
    Randomized crossover trial lasting 20 weeks.
    Summary · context
    Each 10-week arm consisted of a 2-week inpatient dose-adjustment phase followed by an 8-week outpatient phase.
    Summary · context
    A total of 10 patients with hypoparathyroidism were enrolled consecutively over a 15-month period.
    Summary · context
    A dose of PTH 1-34 was administered each morning by subcutaneous injection.
    Summary · context
    Calcitriol was given orally twice daily with supplemental calcium carbonate.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with hypoparathyroidism, once-daily PTH reduced urine calcium excretion compared with calcitriol treatment.

    In plain wordsIn hypoparathyroidism patients, once-daily PTH reduced urine calcium excretion compared with calcitriol and calcium.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseUrine calcium excretion
    Study

    n = 10

    Comparator
    Calcitriol and calcium
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Once daily · subcutaneous · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Once-daily treatment with PTH 1-34 maintained serum calcium in the normal range with decreased urine calcium excretion (P<.05 at 2 weeks and P<.Ol at 10 weeks) compared with calcitriol treatment.
    5 context sentences
    Summary · context
    Randomized crossover trial lasting 20 weeks.
    Summary · context
    Each 10-week arm consisted of a 2-week inpatient dose-adjustment phase followed by an 8-week outpatient phase.
    Summary · context
    A total of 10 patients with hypoparathyroidism were enrolled consecutively over a 15-month period.
    Summary · context
    A dose of PTH 1-34 was administered each morning by subcutaneous injection.
    Summary · context
    Calcitriol was given orally twice daily with supplemental calcium carbonate.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hypoparathyroidism patients, biochemical bone turnover markers increased significantly during PTH treatment.

    In plain wordsIn hypoparathyroidism patients, bone turnover markers increased during PTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBiochemical bone turnover markers
    Study

    n = 10

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Once daily · subcutaneous · 10 weeksAs given in this study (human).

    Source sentences

    Summary
    Biochemical markers of bone turnover increased significantly (P<.Ol at 10 weeks) during PTH 1-34 treatment.
    5 context sentences
    Summary · context
    Randomized crossover trial lasting 20 weeks.
    Summary · context
    Each 10-week arm consisted of a 2-week inpatient dose-adjustment phase followed by an 8-week outpatient phase.
    Summary · context
    A total of 10 patients with hypoparathyroidism were enrolled consecutively over a 15-month period.
    Summary · context
    A dose of PTH 1-34 was administered each morning by subcutaneous injection.
    Summary · context
    Calcitriol was given orally twice daily with supplemental calcium carbonate.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT00001304

Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)n = 27Oct 1991 to Apr 2014

Hypoparathyroidism

Trial pageClinicalTrials.govUpdated 15 Dec 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.